SYRS News and Press, Syros Pharmaceuticals Inc. From 03/07/19

Syros Pharmaceuticals (NASDAQ: SYRS ): Q4 GAAP EPS of -$0.54 misses by $0.03 . More news on: Syros Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...

Expects to Report Updated Data on SY-1425 in Combination with Azacitidine in Newly Diagnosed Unfit AML Patients in Second Half of 2019 Expects to Report Initial Data from Expansion Portion of Phase 1 Trial of SY-1365 in Fourth Quarter of 2019 Announces Plans to Expand Ongoing Phas...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences. Cowen and Company 39 th Annual Health Care Conference in Boston on Wednesday, March 13, 2...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 7, 2019 to report its fourth quarter and full year 2...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical t...

The Portfolio Barometer This article continues the weekly update on market conditions based on the types of portfolios that are outperforming or absent from the list of top-performing stocks. Portfolio strategies may experience the same autocorrelation that sustains strong price movements am...

NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ArcBest Corporation (NASDAQ:ARCB), International Game Technology (NYSE...

Updated Clinical Data on SY-1425 in Combination with Azacitidine Expected in Second Half of 2019 Initial Clinical Data from Expansion Cohorts in Ongoing Phase 1 Trial of SY-1365 Expected in Fourth Quarter of 2019 Advancing SY-5609 Toward Clinical Development with Phase 1 Trial Exp...

SY-1425 in Combination with Azacitidine Shows 63% Overall Response Rate and Rapid Onset of Clinical Responses in RARA or IRF8 Biomarker-Positive Newly Diagnosed Unfit AML Patients Initial Data from Biomarker-Positive and -Negative Azacitidine Combination Cohorts Support Potential Predi...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 30 th Annual Piper Jaffray Healthcare Conference. Details a...